Physician profile
Michael Kurzman
NPI 1295707131
$1,709.23
in general payments reported to CMS, 2019-2025
14 companies · $551 in 2025
The $551 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $11.11 · 2021: $278 · 2022: $415 · 2023: $262 · 2024: $192 · 2025: $551.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,005.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,005.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $458.55 | 2021-2025 | |
| Abbvie INC. | $428.95 | 2021-2025 | |
| Journey Medical Corporation | $230.70 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $123.36 | 2021-2022 | |
| Amgen INC. | $112.80 | 2025 | Otezla, Otezla |
| Pfizer INC. | $105.06 | 2021-2025 | |
| Janssen Biotech, INC. | $87.92 | 2021-2022 | |
| Genentech USA, INC. | $64.73 | 2021-2022 | |
| Leo Pharma INC. | $21.92 | 2022 | |
| Epi Health, LLC | $17.29 | 2021 | |
| Incyte Corporation | $15.89 | 2024 | Opzelura |
| Arcutis Biotherapeutics, INC. | $15.85 | 2023 | |
| Botanix Sb INC | $15.10 | 2025 | Sofdra |
| Galderma Laboratories, L.P. | $11.11 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Kurzman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.